Abstracts tagged "systemic lupus erythematosus (SLE) and transplantation"

Abstract Number: 2921 • 2017 ACR/ARHP Annual Meeting
Improved Survival Following Renal Transplantation in Waitlisted Patients with Systemic Lupus Erythematosus in the United States
April Jorge¹, Zachary S. Wallace², Na Lu³, Yuqing Zhang⁴ and Hyon K. Choi⁵, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Department of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Lupus nephritis is a major complication of systemic lupus erythematosus (SLE), occurring in up to half all SLE patients and progressing to end-stage renal…
Abstract Number: 1610 • 2013 ACR/ARHP Annual Meeting
Lymphoablation Including B Cell Depletion and Autologous Hematopoietic Stem Cell Transplantation Leads To Long Remissions In Treatment-Resistant Systemic Lupus Erythematosus Patients
Sarfaraz A. Hasni¹, Gabor G. Illei², Nikolay P. Nikolov³, Francis Hakim⁴, Susan Leitman⁴, James E. Balow⁵, Howard A. Austin⁶, Juan Gea-Banacloche⁴, Unsong Oh⁷, Paulo Muraro⁸, Claude Sportes⁹, Peter E. Lipsky¹⁰, Ronald Gress⁹, Steve Pavletic⁹ and Amrie Grammer¹¹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Sjogren's Clinic, NIDCR/ NIH, Bethesda, MD, ³NIDCR, NIH, Bethesda, MD, ⁴NCI, NIH, Bethesda, MD, ⁵Clinical Director, NIDDK, National Institutes of Health, Bethesda, MD, ⁶Kidney Disease Section, NIDDK/NIH, Bethesda, MD, ⁷NINDS, NIH, Bethesda, MD, ⁸NINDS/NIH, Bethesda, MD, ⁹NCI/NIH, Bethesda, MD, ¹⁰NIAMS/NIH, Bethesda, MD, ¹¹AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Over the past two decades, approximately 200 patients with severe systemic lupus erythematosus(SLE) have received autologous hematopoietic stem cell transplants (autoHSCT). More than half…
Abstract Number: 1590 • 2013 ACR/ARHP Annual Meeting
A CD8 T Cell-IFN-γ-IDO Axis Is Required For Mesenchymal Stem Cell Suppression Of Human SLE
Dandan Wang¹, Lin Lu², Xuebing Feng³, Xia Li² and Lingyun Sun³, ¹The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ³Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Stem cell-based regenerative medicine is a promising approach in tissue reconstruction. Mesenchymal stem cells (MSC) show therapeutic effects on human autoimmune diseases including systemic…
Abstract Number: 2266 • 2012 ACR/ARHP Annual Meeting
Outcome of Renal Transplantation in Lupus Patients with Positive and Negative Serology: Survival of the Graft and Patients After Transplant
Zahi Touma¹, Murray B. Urowitz², Dominique Ibanez² and D. D. Gladman³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) occurs in 50-75% of adults with SLE and up to 20% of LN patients may advance to end stage renal disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].